CSBio CSBio

X
[{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of the American Academy of Neurology Publishes ProMIS Neurosciences\u2019 Abstracts on Novel Antibody Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"ProMIS Neurosciences"},{"orgOrder":0,"company":"Neurasic Therapeutic","sponsor":"McGill University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurasic Therapeutic Launched to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Neurasic Therapeutic"},{"orgOrder":0,"company":"Cyclica","sponsor":"Arctoris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and Arctoris to Expand Partnership to Advance Drug Discovery Programs for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Cyclica"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem\u2019s Tech Transfer Company, Yissum","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Clearmind Medicine"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The project included rational design of novel candidates, in-silico 3D docking studies on the 5HT2A serotonin receptor, and screening of the candidates in an in-vitro platform, to assess the receptor activation.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimers and other neurodegenerative diseases.

            Lead Product(s): Cyclosporine

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Arctoris

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Neurasic’s potential drug therapy targets acid-sensing ion channels (ASICs), a gene family of neuronal receptors activated by protons that play a role in multiple neurological disorders.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: McGill University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Data showing precision selectivity for neurotoxic TDP-43 and alpha-synuclein publishes in Neurology.

            Lead Product(s): Antibody

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 09, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY